Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR1 | P32246 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.36 |
| ▸ | MAPT | P10636 | 3/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.36 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.35 |
| ▸ | TERT | O14746 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | APEX1 | P27695 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | RBP4 | P02753 | 1/20 | 0.32 |
| ▸ | RRM2 | P31350 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | FGFR4 | P22455 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2373944 | 0.75 | ALDH1A1 (0.41) | CCR1ALDH1A1MAPTSMN1; SMN2PIN1 | |
| SCHEMBL2222443 | 0.74 | ALDH1A1 (0.40) | ALDH1A1MAPTSMN1; SMN2PIN1KDM4E | |
| SCHEMBL19857471 | 0.74 | KDM4E (0.48) | ALDH1A1MAPTSMN1; SMN2PIN1KDM4E | |
| SCHEMBL3901458 | 0.73 | GABRP (0.56) | CCR1ALDH1A1SMN1; SMN2KDM4ETDP1 | |
| SCHEMBL6629423 | 0.73 | CCR1 (0.50) | CCR1ALDH1A1MAPTTERTRRM2 | |
| SCHEMBL847125 | 0.72 | ALDH1A1 (0.39) | ALDH1A1MAPTSMN1; SMN2PIN1KDM4E | |
| SCHEMBL21332489 | 0.72 | ALDH1A1 (0.39) | ALDH1A1MAPTSMN1; SMN2PIN1KDM4E | |
| SCHEMBL20475332 | 0.72 | ALDH1A1 (0.39) | ALDH1A1MAPTSMN1; SMN2PIN1KDM4E | |
| SCHEMBL31715406 | 0.72 | GABRP (0.55) | ALDH1A1MAPTSMN1; SMN2PIN1KDM4E | |
| SCHEMBL1428059 | 0.72 | ALDH1A1 (0.46) | ALDH1A1MAPTSMN1; SMN2PIN1TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250082793-A1 | MACROCYCLIC COMPOUNDS AND METHODS OF MAKING THE SAME | JANSSEN BIOTECH, INC. | 2025-03-13 | — | — | US | claimed |
| EP-4430040-A1 | MACROCYCLIC COMPOUNDS AND METHODS OF MAKING THE SAME | Janssen Biotech, Inc. (US) | 2024-09-18 | — | — | EP | claimed |
| WO-2023084396-A1 | MACROCYCLIC COMPOUNDS AND METHODS OF MAKING THE SAME | JANSSEN BIOTECH, INC. (US) | 2023-05-19 | — | — | WO | claimed |
| US-20250082793-A1 | MACROCYCLIC COMPOUNDS AND METHODS OF MAKING THE SAME | JANSSEN BIOTECH, INC. | 2025-03-13 | — | — | US | disclosed |
| EP-4430040-A1 | MACROCYCLIC COMPOUNDS AND METHODS OF MAKING THE SAME | Janssen Biotech, Inc. (US) | 2024-09-18 | — | — | EP | disclosed |
| EP-3318555-B1 | BIFUNCTIONAL CHELATING AGENTS | BWXT MEDICAL LTD (CA) | 2023-08-16 | — | — | EP | disclosed |
| WO-2023084396-A1 | MACROCYCLIC COMPOUNDS AND METHODS OF MAKING THE SAME | JANSSEN BIOTECH, INC. (US) | 2023-05-19 | — | — | WO | disclosed |
| EP-3318555-A1 | BIFUNCTIONAL CHELATING AGENTS | Nordion (Canada) Inc. (CA) | 2018-05-09 | — | — | EP | disclosed |
| EP-2536691-B1 | BIFUNCTIONAL CHELATING AGENTS | Nordion (Canada) Inc (CA) | 2017-11-22 | — | — | EP | disclosed |
| US-8772446-B2 | Bifunctional chelating agents | NORDION (CANADA) INC. (CA) | 2014-07-08 | — | — | US | disclosed |
| EP-2536691-A1 | BIFUNCTIONAL CHELATING AGENTS | Nordion (Canada) Inc. (CA) | 2012-12-26 | — | — | EP | disclosed |
| US-20080097119-A1 | Disubstituted chalcone oximes having RARgamma retinoid receptor antagonist activity | TSANG KWOK Y | 2008-04-24 | — | — | US | disclosed |
| US-7253319-B2 | Disubstituted chalcone oximes having RARγ retinoid receptor antagonist activity | ALLERGAN, INC. (US) | 2007-08-07 | — | — | US | disclosed |
| EP-1704139-A1 | DISUBSTITUTED CHALCONE OXIMES AS SELECTIVE AGONISTS OF RAR y RETINOID RECEPTORS | Allergan, Inc. (US) | 2006-09-27 | — | — | EP | disclosed |
| EP-1701934-A2 | DISUBSTITUTED CHALCONE OXIMES HAVING RAR(Gamma)-RETINOID RECEPTOR ANTAGONIST ACTIVITY | Allergan, Inc. (US) | 2006-09-20 | — | — | EP | disclosed |
| US-20050165095-A1 | Disubstituted chalcone oximes having RARy retinoid receptor antagonist activity | ALLERGAN, INC. | 2005-07-28 | — | — | US | disclosed |
| WO-2005066116-A1 | DISUBSTITUTED CHALCONE OXIMES AS SELECTIVE AGONISTS OF RARϜ RETINOID RECEPTORS | ALLERGAN, INC. (US) | 2005-07-21 | — | — | WO | disclosed |
| WO-2005066115-A2 | DISUBSTITUTED CHALCONE OXIMES HAVING RARϜ RETINOID RECEPTOR ANTAGONIST ACTIVITY | ALLERGAN, INC. (US) | 2005-07-21 | — | — | WO | disclosed |
| US-20050148590-A1 | Disubstituted chalcone oximes as selective agonists of RAR retinoid receptors | ALLERGAN, INC. | 2005-07-07 | — | — | US | disclosed |
| US-20050148623-A1 | Prevent reproduct of aids virus | ABBVIE INC. | 2005-07-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050148623-A1 | Prevent reproduct of aids virus | SERPINB1, PRSS1, SERPINA3 | CCR1 1559/4885ALDH1A1 1209/4885MAPT 1745/4885 |
| US-20250082793-A1 | MACROCYCLIC COMPOUNDS AND METHODS OF MAKING THE SAME | PAICS, CD47, FURIN | CCR1 106/4885ALDH1A1 2835/4885MAPT 1539/4885 |
| US-20080097119-A1 | Disubstituted chalcone oximes having RARgamma retinoid receptor antagonist activity | RARG, RARB, RARA | CCR1 890/4885ALDH1A1 421/4885MAPT 4778/4885 |
| US-20050165095-A1 | Disubstituted chalcone oximes having RARy retinoid receptor antagonist activity | RARB, RARG, RARA | CCR1 863/4885ALDH1A1 398/4885MAPT 4700/4885 |
| US-20050148590-A1 | Disubstituted chalcone oximes as selective agonists of RAR retinoid receptors | RARG, RXRG, RARB | CCR1 263/4885ALDH1A1 1103/4885MAPT 4165/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.